| |
|
| History |
The Fresenius family began in the pharmaceutical industry in Germany in the 18th Century.
In 1999, Fresenius Kabi was formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi).
|
Global
presence |
Since then, Fresenius Kabi has become a global front-runner in parenteral nutrition business, with offices or manufacturing facilities in Europe, the U.S.A., the Asia-Pacific Region, Middle East & Africa, and now Canada. |
| Innovation |
Fresenius Kabi was the first company in the world to develop a hydroxyethyl starch (HES) colloid, a first generation starch, in 1974. |
| Leadership |
We continue to be leaders in colloid research, developing our volume substitution solutions for the worldwide market. |
| Caring |
All over the world, more than 24,000 employees are committed to improving the quality of life of critically and chronically ill patients. |
|
|
|
|
